Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03003845 · ClinicalTrials.gov registry record
S1P1 Receptor Subtype (S1PR1) Axis in Patients With Interstitial Cystitis (IC) Pain
A clinical trial, sponsored by St. Louis University.
- Completed
- Registry status
- 21
- Enrollment target
NCT03003845: Completed study, sponsored by St. Louis University.
NCT03003845 is a clinical trial that has completed, run by St. Louis University. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03003845 has completed, sponsored by St. Louis University.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
Study Summary
For each patient in the study, blood, and pain scores will be collected to look for markers for pain, at the start of treatment and 6 months after surgery of treatment.
Primary Outcome
S1PR1 levels in PBLs can discriminate patients with Interstitial Cystitis pain and patients with other types of pain.
Interventions
- OTHER Questionnaires
- OTHER Collection of Blood samples
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2019-02-26 |
| Est. Completion | 2020-02-27 |
What the finished NCT03003845 record still lists
NCT03003845 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Questionnaires is the first listed.
NCT03003845 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03003845 about?
NCT03003845 is a clinical study titled "S1P1 Receptor Subtype (S1PR1) Axis in Patients With Interstitial Cystitis (IC) Pain". For each patient in the study, blood, and pain scores will be collected to look for markers for pain, at the start of treatment and 6 months after surgery of treatment.
What is the current status of trial NCT03003845?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2019-02-26. Estimated completion is 2020-02-27.
What interventions are being tested in trial NCT03003845?
The interventions under investigation include: Questionnaires (OTHER), Collection of Blood samples (OTHER).
Who is sponsoring clinical trial NCT03003845?
This trial is sponsored by St. Louis University, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI